Substantia nigra hyperechogenicity in healthy controls: a [18Fluoro] Dopa-PET follow-up study

被引:2
|
作者
Schroeder, Ute [1 ]
Behnke, Stefanie [1 ]
Buchholz, Hans-Georg [2 ]
Fassbender, Klaus [1 ]
Schreckenberger, Matthias [2 ]
Berg, Daniela [3 ,4 ]
机构
[1] Saarland Univ Hosp, Dept Neurol, D-66421 Homburg, Germany
[2] Johannes Gutenberg Univ Mainz, Dept Nucl Med, D-55131 Mainz, Germany
[3] Univ Tubingen, Dept Neurodegenerat, Ctr Neurol, D-72076 Tubingen, Germany
[4] Univ Tubingen, Hertie Inst Clin Brain Res, Ctr Neurol, D-72076 Tubingen, Germany
关键词
Substantia nigra hyperechogenicity; Transcranial ultrasound; Parkinson's disease; (18)Fluoro] Dopa-PET; PARKINSONS-DISEASE; ECHOGENICITY;
D O I
10.1007/s00415-013-6904-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In order to assess nigrostriatal function over time in healthy subjects with substantia nigra hyperechogenicity (SN+) believed to be at higher risk for Parkinson's disease (PD), ten healthy SN+ subjects underwent [(18)Fluoro] Dopa positron emission tomography (PET) twice-at baseline and after a mean of 7.3 years. Neurological examination took place at study inclusion followed by a structured telephone interview focusing on early Parkinsonian symptoms at the time point of second PET study and 3.5 years later. The [(18)Fluoro] Dopa uptake remained unchanged in eight of ten participants. In the other two subjects marked unilateral reduction of putaminal [(18)Fluoro] Dopa uptake ratios appeared over the time, followed by complaints of a clinically manifest PD in one. We suggest that the progressive pathological PET findings in 20 % and PD conversion in 10 % of our cohort may be in accordance with the presumed proportion of SN+ individuals eventually developing PD based on SN+ prevalence of 10 % within the healthy population, being ten times higher than PD prevalence in the age of over 60 years. Our findings hint towards a significance of SN+ indicating a high risk for PD in some extrapyramidally healthy SN+ individuals.
引用
收藏
页码:1907 / 1911
页数:5
相关论文
共 50 条
  • [21] Hybrid [18F]-F-DOPA PET/MRI Interpretation Criteria and Scores for Glioma Follow-up After Radiotherapy
    Marc Bertaux
    Arnaud Berenbaum
    Anna-Luisa Di Stefano
    Laura Rozenblum
    Marine Soret
    Sebastien Bergeret
    Khé Hoang-Xuan
    Laure-Eugenie Tainturier
    Brian Sgard
    Marie-Odile Habert
    Jean-Yves Delattre
    Caroline Dehais
    Ahmed Idbaih
    Nadya Pyatigorskaya
    Aurelie Kas
    Clinical Neuroradiology, 2022, 32 : 735 - 747
  • [22] Responses to intravenous glucose non-diabetic twins and healthy controls: a prospective follow-up study
    Hawa, MI
    Valeri, C
    Castelli, MD
    Bonfante, R
    Beyan, H
    Leslie, RDG
    DIABETOLOGIA, 2004, 47 : A173 - A173
  • [23] Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease:: A two-year follow-up study
    Bruck, Anna
    Aalto, Sargo
    Nurmi, Elina
    Vahlberg, Tero
    Bergman, Jogen
    Rinne, Juha O.
    MOVEMENT DISORDERS, 2006, 21 (07) : 958 - 963
  • [24] 18F-FLUTEMETAMOL PET POST-STROKE - A SEVEN YEAR FOLLOW-UP STUDY
    Hagberg, G.
    Ihle-Hansen, H.
    Fure, B.
    Thommessen, B.
    Ihle-Hansen, H.
    Oksengard, A.
    Beyer, M.
    Wyller, T.
    Mueller, E.
    Pendlebury, S.
    Selnes, P.
    INTERNATIONAL JOURNAL OF STROKE, 2020, 15 (1_SUPPL) : 555 - 556
  • [25] Siliconomas as an incidental finding in an 18F-FDG PET/CT study at follow-up of colon cancer
    Sandoval-Moreno, C.
    Tagliatori-Nogueira, M. B.
    de la Rubia-Marcos, M.
    Manzarbeitia-Arroba, B.
    Alvarez-Moreno, M.
    Balsa-Breton, M. A.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2022, 41 (05): : 327 - 328
  • [26] FETAL MESENCEPHALIC TRANSPLANTATION IN PARKINSONS-DISEASE (PD) - FOLLOW-UP IN 5 PATIENTS WITH POSITRON EMISSION TOMOGRAPHY (PET) AND [F-18] FLUORODOPA (F-18-DOPA)
    REMY, P
    SAMSON, Y
    HANTRAYE, P
    DEFER, G
    FENELON, G
    BENDRIEM, B
    FROUIN, V
    NGUYEN, JP
    DEGOS, JD
    PESCHANSKI, M
    CESARO, P
    NEUROLOGY, 1994, 44 (04) : A281 - A281
  • [27] Comparison of 18FDG-PET/CT and conventional follow-up methods in colorectal cancer: A randomised prospective study
    Monteil, Jacques
    Le Brun-Ly, Valerie
    Cachin, Florent
    Zasadny, Xavier
    Seitz, Jean-Francois
    Mundler, Olivier
    Selvy, Marie
    Smith, Denis
    Rullier, Eric
    Lavau-Denes, Sandrine
    Lades, Guillaume
    Labrunie, Anais
    Lecaille, Cedric
    Valli, Nathalie
    Leobon, Sophie
    Terrebonne, Eric
    Deluche, Elise
    Tubiana-Mathieu, Nicole
    DIGESTIVE AND LIVER DISEASE, 2021, 53 (02) : 231 - 237
  • [28] Prognostic value of 18 FDG-PET at diagnosis and follow-up in giant cell arteritis: An observational restrospective study
    Billet, Anne-Claire
    Thibault, Thomas
    Liozon, Eric
    De Boysson, Hubert
    Perard, Laurent
    Espitia, Olivier
    Daumas, Aurelie
    Pinho, Quentin Gomes De
    Durel, Cecile-Audrey
    Hot, Arnaud
    Bienvenuj, Boris
    Humbertk, Sebastien
    Bachmeyerl, Claude
    Sene, Thomas
    Mainbourgm, Sabine
    Devilliers, Herve
    Bailloud, Bastien Durand
    Greigert, Helene
    Cochet, Alexandre
    Bonnotte, Bernard
    Alberini, Jean-Louis
    Samson, Maxime
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 126 : 69 - 76
  • [29] Metabolomic profiles in relapsing–remitting and progressive multiple sclerosis compared to healthy controls: a five-year follow-up study
    Tiange Shi
    Richard W. Browne
    Miriam Tamaño-Blanco
    Dejan Jakimovski
    Bianca Weinstock-Guttman
    Robert Zivadinov
    Murali Ramanathan
    Rachael H. Blair
    Metabolomics, 19
  • [30] 18F-FDG PET/CT in the follow-up of large-vessel vasculitis: A study of 37 consecutive patients
    Martinez-Rodriguez, Isabel
    Jimenez-Alonso, Mikel
    Quirce, Remedios
    Jimenez-Bonilla, Julio
    Martinez-Amador, Nestor
    De Arcocha-Torres, Maria
    Loricera, Javier
    Blanco, Ricardo
    Gonzalez-Gay, Miguel A.
    Banzo, Ignacio
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018, 47 (04) : 530 - 537